Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
15 - May - 2025 12:00 | 9 days ago
Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024.
For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024.
Caplin Point Laboratories fixes record date for interim dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories has fixed 30 May 2025 as record date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.
Board of Caplin Point Laboratories recommends dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.
Caplin Point Laboratories fixes record date for interim dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories has fixed 30 May 2025 as record date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.
Board of Caplin Point Laboratories recommends dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.
Caplin Steriles receives USFDA approval for Haloperidol Decanoate Injection
14 - May - 2025 12:00 | 10 days ago
Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Decanoate Injection, 50mg/mL and 100mg/mL Single Dose Vials; 500mg/5mL (100mg/mL) Multiple-Dose Vials, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) HALDOL (haloperidol decanoate) Injection, by Janssen Pharmaceuticals Inc.
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy.
According to IQVIATM (IMS Health), Haloperidol Decanoate Injection had US sales of approximately $16.4 million for the 12 month period ending March 2025.
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
15 - May - 2025 12:00 | 9 days ago
Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024.
For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024.
Caplin Point Laboratories fixes record date for interim dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories has fixed 30 May 2025 as record date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.
Board of Caplin Point Laboratories recommends dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.
Caplin Steriles receives USFDA approval for Haloperidol Decanoate Injection
14 - May - 2025 12:00 | 10 days ago
Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Decanoate Injection, 50mg/mL and 100mg/mL Single Dose Vials; 500mg/5mL (100mg/mL) Multiple-Dose Vials, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) HALDOL (haloperidol decanoate) Injection, by Janssen Pharmaceuticals Inc.
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy.
According to IQVIATM (IMS Health), Haloperidol Decanoate Injection had US sales of approximately $16.4 million for the 12 month period ending March 2025.
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
15 - May - 2025 12:00 | 9 days ago
Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024.
For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024.
Caplin Point Laboratories fixes record date for interim dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories has fixed 30 May 2025 as record date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.
Board of Caplin Point Laboratories recommends dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.
Caplin Point Laboratories fixes record date for interim dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories has fixed 30 May 2025 as record date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.
Board of Caplin Point Laboratories recommends dividend
15 - May - 2025 12:00 | 9 days ago
Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.
Caplin Steriles receives USFDA approval for Haloperidol Decanoate Injection
14 - May - 2025 12:00 | 10 days ago
Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Decanoate Injection, 50mg/mL and 100mg/mL Single Dose Vials; 500mg/5mL (100mg/mL) Multiple-Dose Vials, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) HALDOL (haloperidol decanoate) Injection, by Janssen Pharmaceuticals Inc.
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy.
According to IQVIATM (IMS Health), Haloperidol Decanoate Injection had US sales of approximately $16.4 million for the 12 month period ending March 2025.
